In patients with TNM stages I + II HCC, high expression of PRMT1, PRMT3, and PRMT6, and low expression of PRMT9 were significantly associated with decreased survival (Figure 4A), with PRMT1 displaying the most pronounced effect. Here, PRMT9 is linked to hepatocellular carcinoma.